Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aridis Pharmaceuticals stock | $7.3

Own Aridis Pharmaceuticals stock in just a few minutes.

Fact checked

Aridis Pharmaceuticals, Inc is a biotechnology business based in the US. Aridis Pharmaceuticals shares (ARDS) are listed on the NASDAQ and all prices are listed in US Dollars. Aridis Pharmaceuticals employs 25 staff and has a trailing 12-month revenue of around USD$1 million.

How to buy shares in Aridis Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aridis Pharmaceuticals. Find the stock by name or ticker symbol: ARDS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aridis Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$7.3, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aridis Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aridis Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aridis Pharmaceuticals share price

Use our graph to track the performance of ARDS stocks over time.

Aridis Pharmaceuticals shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$7.3
52-week rangeUSD$3.8 - USD$10
50-day moving average USD$6.8503
200-day moving average USD$6.9661
Wall St. target priceUSD$17.2
PE ratio 2.834
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.187

Buy Aridis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aridis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aridis Pharmaceuticals price performance over time

Historical closes compared with the close of $7.3 from 2020-12-09

1 week (2021-01-07) 21.67%
1 month (2020-12-17) 5.95%
3 months (2020-10-15) -7.01%
6 months (2020-07-15) 10.11%
1 year (2020-01-15) -3.69%
2 years (2019-01-15) -17.05%
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Is Aridis Pharmaceuticals under- or over-valued?

Valuing Aridis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aridis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Aridis Pharmaceuticals's P/E ratio

Aridis Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Aridis Pharmaceuticals shares trade at around 3x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Aridis Pharmaceuticals financials

Revenue TTM USD$1 million
Gross profit TTM USD$-23,061,000
Return on assets TTM -59.89%
Return on equity TTM 0%
Profit margin 0%
Book value $0.985
Market capitalisation USD$66 million

TTM: trailing 12 months

Shorting Aridis Pharmaceuticals shares

There are currently 8,248 Aridis Pharmaceuticals shares held short by investors – that's known as Aridis Pharmaceuticals's "short interest". This figure is 28.4% down from 11,526 last month.

There are a few different ways that this level of interest in shorting Aridis Pharmaceuticals shares can be evaluated.

Aridis Pharmaceuticals's "short interest ratio" (SIR)

Aridis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aridis Pharmaceuticals shares currently shorted divided by the average quantity of Aridis Pharmaceuticals shares traded daily (recently around 19181.395348837). Aridis Pharmaceuticals's SIR currently stands at 0.43. In other words for every 100,000 Aridis Pharmaceuticals shares traded daily on the market, roughly 430 shares are currently held short.

However Aridis Pharmaceuticals's short interest can also be evaluated against the total number of Aridis Pharmaceuticals shares, or, against the total number of tradable Aridis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aridis Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Aridis Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0007% of the tradable shares (for every 100,000 tradable Aridis Pharmaceuticals shares, roughly 1 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aridis Pharmaceuticals.

Find out more about how you can short Aridis Pharmaceuticals stock.

Aridis Pharmaceuticals share dividends

We're not expecting Aridis Pharmaceuticals to pay a dividend over the next 12 months.

Aridis Pharmaceuticals share price volatility

Over the last 12 months, Aridis Pharmaceuticals's shares have ranged in value from as little as $3.8 up to $10. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aridis Pharmaceuticals's is 0.2107. This would suggest that Aridis Pharmaceuticals's shares are less volatile than average (for this exchange).

Aridis Pharmaceuticals overview

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site